THE INFLUENCE OF FOOD ON THE DISPOSITION OF THE ANTIEPILEPTIC OXCARBAZEPINE AND ITS MAJOR METABOLITES IN HEALTHY-VOLUNTEERS

被引:29
作者
DEGEN, PH [1 ]
FLESCH, G [1 ]
CARDOT, JM [1 ]
CZENDLIK, C [1 ]
DIETERLE, W [1 ]
机构
[1] CIBA GEIGY LTD,DIV PHARMACEUT,PRECLIN DEV,BASEL,SWITZERLAND
关键词
OXCARBAZEPINE; METABOLITES; ANTIEPILEPTIC; DISPOSITION; FOOD;
D O I
10.1002/bdd.2510150609
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of food on the pharmacokinetics of the antiepileptic oxcarbazepine (OXC) was investigated in healthy volunteers. Six healthy male volunteers were treated with single peroral doses of 600 mg of oxcarbazepine (Trileptal(R)) after overnight fasting or a fat- and protein-rich breakfast. Mean (+/-SD) areas under the plasma concentration-time curves (AUC) of the major component in plasma, the active monohydroxy metabolite (MHD), which is responsible for the therapeutic effect in man, were 672 (25) mu mol L(-1) h when given to the fasted volunteers and 780 (31) mu mol L(-1) h (p = 0.042) when given after a substantial breakfast. Mean (+/-SD) maximum concentrations (C-max) were 25.5 (4.8)mu mol L(-1) when given to the fasted volunteers and 31.4(5.3) mu mol L(-1) (p = 0.025) when given after breakfast. Thus, the average AUC was increased by 16% and C-max by 23% when oxcarbazepine was given with food. The times at which C-max was reached (t(max)) as well as the terminal half-lives were not influenced by concomitant intake of food. The tolerability was the same whether oxcarbazepine was given before or after food in healthy volunteers. The slight effect of food on the kinetics of oxcarbazepine should be of little therapeutic consequence.
引用
收藏
页码:519 / 526
页数:8
相关论文
共 9 条
[1]  
DICKINSON RG, 1989, EUR J CLIN PHARMACOL, V37, P69
[2]  
FAIGLE JW, 1990, INT CLIN PSYCHOPHARM, V5, P73
[3]   PHARMACOKINETICS OF 10-OH-CARBAZEPINE, THE MAIN METABOLITE OF THE ANTI-EPILEPTIC OXCARBAZEPINE, FROM SERUM AND SALIVA CONCENTRATIONS [J].
KRISTENSEN, O ;
KLITGAARD, NA ;
JONSSON, B ;
SINDRUP, S .
ACTA NEUROLOGICA SCANDINAVICA, 1983, 68 (03) :145-150
[4]   LACK OF ENZYME-INDUCTION WITH OXCARBAZEPINE (600 MG DAILY) IN HEALTHY-SUBJECTS [J].
LARKIN, JG ;
MCKEE, PJW ;
FORREST, G ;
BEASTALL, GH ;
PARK, BK ;
LOWRIE, JI ;
LLOYD, P ;
BRODIE, MJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 31 (01) :65-71
[5]   DETERMINATION OF OXCARBAZEPINE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
MENGE, G ;
DUBOIS, JP .
JOURNAL OF CHROMATOGRAPHY, 1983, 275 (01) :189-194
[6]   ANALYTICAL METHODS VALIDATION - BIOAVAILABILITY, BIOEQUIVALENCE, AND PHARMACOKINETIC STUDIES [J].
SHAH, VP ;
MIDHA, KK ;
DIGHE, S ;
MCGILVERAY, IJ ;
SKELLY, JP ;
YACOBI, A ;
LAYLOFF, T ;
VISWANATHAN, CT ;
COOK, CE ;
MCDOWALL, RD ;
PITTMAN, KA ;
SPECTOR, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (03) :309-312
[7]  
TEDESCHI G, 1981, ADV EPILEPTOL, P563
[8]   DISPOSITION OF THE ANTI-EPILEPTIC OXCARBAZEPINE AND ITS METABOLITES IN HEALTHY-VOLUNTEERS [J].
THEISOHN, M ;
HEIMANN, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 22 (06) :545-551
[9]   THE INFLUENCE OF AGE ON THE PHARMACOKINETICS OF THE ANTIEPILEPTIC AGENT OXCARBAZEPINE [J].
VANHEININGEN, PNM ;
EVE, MD ;
OOSTERHUIS, B ;
JONKMAN, JHG ;
DEBRUIN, H ;
HULSMAN, JARJ ;
RICHENS, A ;
JENSEN, PK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (04) :410-419